Author

Zhengguo Li

Institution: Yixing Tumor Hospital

Observed institutions: Chongqing University, Gansu Provincial Cancer Hospital Gansu Provincial Academic Instiute for Medical Research, Yixing Tumor Hospital, Sun Yat-sen University Cancer Center, Xi'an Jiaotong University

ORCID: 0000-0002-6029-2178

Observed ORCID: 0000-0002-6029-2178

OpenAlex ID: A5100700919

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

2025 · Zhiwei Chen, Fang Yang, et al. · The Lancet · 63

circ _0007385 served as competing endogenous RNA for miR ‐519d‐3p to suppress malignant behaviors and cisplatin resistance of non‐small cell lung cancer cells

2020 · Yancheng Ye, Liangcun Zhao, et al. · Thoracic Cancer · 55

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China

2026 · Shun Lu, Baogang Liu, et al. · The Lancet · 24

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

2025 · Lin Wang, Xuezhi Hao, et al. · The Lancet Respiratory Medicine · 11

Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma

2024 · Baokun Liu, Lujun Shen, et al. · Journal of Hepatocellular Carcinoma · 4

A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.

2025 · Pu-Yuan Xing, Ligang Xing, et al. · Journal of Clinical Oncology · 2

Circular RNAs in Brain Disorders

2019 · Ruirui Jia, Zhengguo Li, et al. · Med One · 2

Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial

2024 · Da Zhao, Zhengguo Li, et al. · Frontiers in Oncology · 1

Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non–small-cell lung cancer: a randomized, multicenter, phase II trial

2026 · Mengjie Li, Caixia Liu, et al. · Cancer Biology and Medicine

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study

2026 · Zhiwei Chen, Fang Yang, et al. · Future Oncology

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study

2026 · Zhiwei Chen, Fang Yang, et al. · Figshare

Efbemalenograstim alfa for prophylaxis in non–small cell lung cancer patients patients with chemotherapy-induced febrile neutropenia: A randomized, multicenter, exploratory clinical trial.

2026 · Mengjie Li, Dingzhi Huang, et al. · Journal of Clinical Oncology

[First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion].

2024 · Zhengguo Li, Ting Wei, et al. · PubMed Central

Works count: 13

Citation count: 162

H-index: 4

I10-index: 4